Indicated for: leukemia
Route of administration: oral
Substance: mercaptopurine (antimetabolite antineoplastic)
ATC: L01BB02 (Antineoplastic and immunomodulating agents | Antimetabolites | Purine analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
A genetic test may be needed before treatment.
Mercaptopurine is a medication used for the treatment of acute lymphoblastic leukemia and other hematological conditions. It works by inhibiting DNA synthesis in cancer cells, thereby preventing their proliferation.
The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor liver and hematologic function.
Patients should be aware of potential side effects, such as nausea, decreased blood cell counts, or liver impairment. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, decreased blood cell counts, and liver impairment. In rare cases, severe reactions such as liver failure or severe infections may occur. Patients should be informed of these risks before use.